LXW7-CB-TE2A

LXW7-CB-TE2A is a radiolabeled peptide-based imaging agent developed for the targeting and visualization of glioblastoma. It consists of the LXW7 peptide, which contains an RGD motif and specifically targets the **αvβ3 integrin** expressed on glioblastoma cells and tumor-associated endothelial cells. The peptide is conjugated to the cross-bridged macrocyclic chelator **CB-TE2A** (1,4,8,11-tetraazacyclotetradecane-1,8-diacetic acid), which is complexed with the positron-emitting radioisotope **Copper-64 (64Cu)**. This conjugate is primarily used for positron emission tomography (PET) imaging to assess tumor accumulation and biodistribution. Research indicates that while it effectively targets glioblastoma xenografts, its high uptake in the liver and kidney suggests it is more suitable for diagnostic imaging than for targeted radiotherapy in its current form.

Other names

64Cu-labeled LXW7-CB-TE2ALXW7-CB-TE2A conjugateLXW-7-CB-TE2A conjugateLXW 7-CB-TE2A conjugate